Paid Clinical Trials Dayton

Discover 1,262 paid clinical trials in Dayton, Ohio. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,262

Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Dayton OH, Kettering OH, Beavercreek OH, Centerville OHshow 269 more

Code:

NCT05095376

Conditions

Glioblastoma

Gliosarcoma

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

Lomustine

Magnetic Resonance Imaging

Photon Beam Radiation Therapy

Questionnaire Administration

Temozolomide

NONO During CPB in Neonates to Reduce Risk of AKI

Recruiting

PHASE3

Sponsor:

Children's Hospital Medical Center, Cincinnati

Location:

Cincinnati OH

Code:

NCT04216927

Conditions

AKI

CHD - Congenital Heart Disease

Surgery

Eligibility Criteria

Sex: All

Age: 1 - 31

Healthy Volunteers: Not accepted

Interventions

Nitric Oxide

Oxygen

AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine

Recruiting

PHASE3

Sponsor:

AbbVie

Location:

Cincinnati OH, West Chester OH, Ann Arbor MI, Newburgh INshow 35 more

Code:

NCT05711394

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Atogepant

Placebo-Matching Atogepant

Optimizing TreatmentOptimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach

Recruiting

PHASE3

Sponsor:

HELP for NOWS Consortium

Location:

Kettering OH, Cincinnati OH, Edgewood KY, Indianapolis INshow 16 more

Code:

NCT05980260

Conditions

Neonatal Opiate Withdrawal Syndrome

Eligibility Criteria

Sex: All

Age: 1 - 48

Healthy Volunteers: Not accepted

Interventions

Symptom-based Dosing Approach

Scheduled Opioid Taper Approach

Cema-celConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Cincinnati OH, Indianapolis IN, Lexington KY, Louisville KYshow 33 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

AP-CD/LDA Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

Recruiting

PHASE3

Sponsor:

Intec Pharma Ltd.

Location:

Cincinnati OH, Toledo OH, Farmington Hills MI, West Bloomfield MIshow 32 more

Code:

NCT02615873

Conditions

Parkinson's Disease

Eligibility Criteria

Sex: All

Age: 30 - 70+

Healthy Volunteers: Not accepted

Interventions

Accordion Pill™ Carbidopa/Levodopa

DupilumabA Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Recruiting

PHASE2

PHASE3

Sponsor:

Regeneron Pharmaceuticals

Location:

Cincinnati OH, Columbus OH, Ann Arbor MI, Mentor OHshow 42 more

Code:

NCT05831176

Conditions

Eosinophilic Gastritis

Eosinophilic Duodenitis

Eosinophilic Gastrointestinal Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Dupilumab Dose 1

Dupilumab Dose 2

Matching Placebo

Ferric CitrateStudy to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease

Recruiting

PHASE3

Sponsor:

Keryx Biopharmaceuticals

Location:

Cincinnati OH, Grand Rapids MI, Baltimore MD, Birmingham ALshow 10 more

Code:

NCT04523727

Conditions

Hyperphosphatemia Related to Chronic Kidney Disease

Eligibility Criteria

Sex: All

Age: 6 - 16

Healthy Volunteers: Not accepted

Interventions

ferric citrate

ESISESIS in Pediatric DRE

Recruiting

Sponsor:

Sarah Katie Ihnen

Location:

Cincinnati OH

Code:

NCT05469373

Conditions

Epilepsy

Eligibility Criteria

Sex: All

Age: 1 - 30

Healthy Volunteers: Not accepted

Ustekinumab & GuselkumabA Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis

Recruiting

PHASE3

Sponsor:

Janssen Research & Development, LLC

Location:

Cincinnati OH, Chapel Hill NC, New York NY, Bronx NYshow 4 more

Code:

NCT05083182

Conditions

Arthritis, Juvenile

Eligibility Criteria

Sex: All

Age: 5 - 17

Healthy Volunteers: Not accepted

Interventions

Ustekinumab

Guselkumab